Table 2.

Serum gastrin and pepsinogen levels and H. pylori antibodies of males with differentiated-type lesions undergoing metachronous and non-metachronous GCAE who had not been using proton pump inhibitors.

Variables	Metachronous (+), 13 Patients 19 Lesions	Metachronous (−), 50 Patients 55 Lesions	p-Value
Serum gastrin (pg/mL)	109 (70–222)	75.5 (31–157)	0.026 *
Serum PG I (ng/mL)	28.8 (8.2–110.1)	42 (20.3–157.7)	0.757
Serum PG II (ng/mL)	8.2 (5.2–16.5)	8 (3.8–27.6)	0.709
PG I/II ratio	4.2 (0.8–7.8)	5.3 (1.7–9.4)	0.036 *

GCAE: gastric cancer after eradication; PG, pepsinogen; *: a significant difference.